Search Clinical Trials
 
By Condition
 
By Location (USA)
 
By Location (Other)
 
By Sponsor
 
Resources
 
Privacy Policy
 
About Us
Disclaimer
Antibiotic treatment trial directed against Chlamydia pneumonia in multiple sclerosis Clinical Trials Info presented on Clinical Trials Search is not intended to be a substitute for certified medical advice, visits or professional assistance using a real physician. We are not physicians. Always consult your dr. about Antibiotic treatment trial directed against Chlamydia pneumonia in multiple sclerosis conditions. Clinical Trials Search.org is a site dedicated to listing clinical research studies in human subjects. Antibiotic treatment trial directed against Chlamydia pneumonia in multiple sclerosis Clinical research trials and Antibiotic treatment trial directed against Chlamydia pneumonia in multiple sclerosis health trials happen in many of localities throughout the U.S.. A clinical trial or clinical study is a research project with human volunteer subjects. Clinical drug trials and pharmaceutical clinical trials typically measure the effectualness of new drugs. The function of the studies / projects is to resolve particular human medical questions. Clinical trials are a popular manner for mDs, government agencies, and private sector corporations to discover remedies for all varieties of circumstances, like Antibiotic treatment trial directed against Chlamydia pneumonia in multiple sclerosis. Antibiotic treatment trial directed against Chlamydia pneumonia in multiple sclerosis Clinical Trials and other clinical trials allow volunteers to obtain healthcare treatment options before they are available to the masses. Some times the participants undergo professional assistance for free of charge, and occasionally they are paid for their time. Sometimes there is a cost for a Antibiotic treatment trial directed against Chlamydia pneumonia in multiple sclerosis clinical trial. Human subjects often get the best healthcare available for their Antibiotic treatment trial directed against Chlamydia pneumonia in multiple sclerosis condition. Dangers are a reality, however, and may include additional or frequent mD visits, healthcare dangers (potentially life-jeopardising), and/or the treatment being ineffectual. Trials are federally governed with rigorous guidelines to protect clinical trials patients.

Home > "A" Clinical Trials Conditions > Antibiotic treatment trial directed against Chlamydia pneumonia in multiple sclerosis

Antibiotic treatment trial directed against Chlamydia pneumonia in multiple sclerosis



Antibiotic treatment trial directed against Chlamydia pneumonia in multiple sclerosis

For Condition: Multiple Sclerosis
Status: Completed
Sponsor(s): National Center for Research Resources (NCRR) , National Multiple Sclerosis Society
Synopsis: Multiple sclerosis (MS) is an inflammatory, demyelinating disease which affects the central nervous system (CNS). The etiology of MS is unknown, although the immune system appears to play a role. Many different infectious agents have been proposed as potential causes for MS, including Epstein-Barr virus, human herpesvirus 6, and coronaviruses. Recently Dr. Sriram at Vanderbilt University has found evidence for active Chlamydia pneumonia infection in the CNS of MS patients. These findings have been replicated in part by other laboratories. The purpose of the current study is to test whether antibiotic treatment aimed at eradicating Chlamydia infection will reduce the disease activity in MS. The primary outcome measure will be reduction in new enhancing MS lesions on brain MRI. Forty patients will be entered into the trial. To be eligible, patients must have evidence of chlamydia infection in their spinal fluid and enhancing lesions on their pre-randomization MRI scans. Patients who meet these criteria will be randomized to either placebo or antibiotic therapy, and followed for 6 months on treatment.
Details:
Eligibility:
Study Type:  Interventional, Treatment, Double-Blind, Placebo Control, Parallel Assignment
Minimum Age/Maximum Age: 18 Years/65 Years
Genders: Both
Protocol Entry Criteria: Patients with unequivocal diagnosis of multiple sclerosis and have evidence of C. pneumoniae infection in the cerebral spinal fluid
Total Enrollment: 40

Location and Contact Information:

University of Texas Medical School
Houston,  Texas,  77030
United States
 


Additional Information:
Study ID Numbers:  NCRR-M01RR02558-0176; 
Study Start Date: 
Record last reviewed: December 2003
Additional information available at: clinicaltrials.gov
Clinicaltrials.gov Reference link: NCT00043264

Other Multiple Sclerosis Studies:
1. A study to evaluate the preliminary efficacy pharmacokinetics and immunogenicity of BMS-188667 administered to subjects with relapsing-remitting multiple sclerosis

2. Rolipram to Treat Multiple Sclerosis

3. Evaluation of an Altered Peptide Ligand (NBI-5788) in Patients with Relapsing Multiple Sclerosis (MS)

4. Assessment of Patients with Multiple Sclerosis (MS)

5. Evaluation of Lyme Disease: Clinical, Microbiological and Immunological Characteristics

Related Studies:

Other Multiple Sclerosis Clinical Trials
Other Texas Clinical Trials
Other Houston Clinical Trials

Antibiotic treatment trial directed against Chlamydia pneumonia in multiple sclerosis
Modify your Search

  Other Multiple Sclerosis Clinical Trials
  Other Texas Clinical Trials
  Other Houston Clinical Trials


Warning: include(/var/www/cgi-bin/traxis/counter.php) [function.include]: failed to open stream: No such file or directory in /home/cts/domains/clinicaltrialssearch.org/public_html/index.php on line 103

Warning: include() [function.include]: Failed opening '/var/www/cgi-bin/traxis/counter.php' for inclusion (include_path='.:/usr/local/lib/php') in /home/cts/domains/clinicaltrialssearch.org/public_html/index.php on line 103